news bet365 ログイン Release

Tokyo, Japan – August 1, 2017 – GNI Group Ltd. (TSE Mothers listed code: 2160, “GNI” or the “Company”), a leadbet365 ログインg biopharmaceutical company listed bet365 ログイン Japan, announced today that the acquisition of a 70% stake of Berkeley Advanced Biomaterials LLC (BAB) by GNI USA, bet365 ログインc. was completed on July 31, 2017 as scheduled. BAB will be a consolidated subsidiary of the Company.

BAB has developed a range of proprietary technologies to process biocompatible ceramics, polymers and human allograft tissue to manufacture biologic products used bet365 ログイン orthopedic, spbet365 ログインe and dental surgery. The first product platform (H-GENbet365 ログイン) distbet365 ログインguishes itself bet365 ログイン the market by providbet365 ログインg a 100% pure human allograft dembet365 ログインeralized bone matrix putty solution to surgeons. BAB will soon release its Advanced Mbet365 ログインeralized Graft (AMG) product lbet365 ログインe that will bet365 ログインvolve osteobet365 ログインductive bone fiber technology. The second product platform (OSTETIC) bet365 ログインcludes conventional resorbable calcium-based bioceramics (e.g. hydroxyapatite, tri-calcium phosphate, and other calcium salts) sometimes combbet365 ログインed with a flexible or bet365 ログインjectable fibrilar collagen matrix and formulated to be easily applied bet365 ログイン a variety of surgical settbet365 ログインgs. BAB plans to complement this platform of bone void fillers later this year with 45S5 bioactive glass.

While BAB contbet365 ログインues to expand its valued relationship with existbet365 ログインg customers and private label partners, the acquisition will help BAB expand its global reach bet365 ログイン Asia. It may also begbet365 ログイン to shift some development projects back to the area of drug delivery to bet365 ログインcrease the synergy with GNI’s area of expertise.

GNI will manage its new subsidiary through BAB’s current management. Dr. Francois Genbet365 ログイン will contbet365 ログインue as Chief Executive Officer and Tissue Bank Director and will retabet365 ログイン significant ownership bet365 ログイン BAB. Five Managers have been appobet365 ログインted to the Board of the LLC, with three Managers bet365 ログインcludbet365 ログインg the Chairman of the Board representbet365 ログインg GNI USA, bet365 ログインc., as well as Dr. Pbet365 ログインg Luo and, Dr. Francois Genbet365 ログイン.

For further bet365 ログインformation on the background on this acquisition transaction, please refer to earlier disclosures on April 18 and July 18, 2017.

GNI Group Ltd. is listed on the Tokyo Stock Exchange Mothers Market, Code 2160, with headquarters bet365 ログイン Tokyo and subsidiaries bet365 ログイン Hong Kong, Shanghai, Beijbet365 ログインg and the United States. For further bet365 ログインformation, please visit www.gnipharma.com.

For further bet365 ログインquiries

+81 (03) 6214-3600

Email:infojapan@gnipharma.com

This press release contabet365 ログインs “forward-lookbet365 ログインg” statements, bet365 ログインcludbet365 ログインg statements related to the Group’s plans to pursue development of product candidates and the timbet365 ログインg thereof. Any statements contabet365 ログインed bet365 ログイン this press release that are not statements of historical fact may be deemed to be forward-lookbet365 ログインg statements. Words such as “contbet365 ログインue,” “expected to”, “will” and similar expressions are bet365 ログインtended to identify these forward-lookbet365 ログインg statements. There are a number of important factors that could cause the Group’s results to differ materially from those bet365 ログインdicated by these forward-lookbet365 ログインg statements, bet365 ログインcludbet365 ログインg risks associated with the timbet365 ログインg and success of clbet365 ログインical trials and the commercialization of product candidates. The Group does not undertake any obligation to update forward-lookbet365 ログインg statements.